Background: Type 2 diabetes and diabetic dyslipidemia are high-risk conditions for cardiovascular disease. However, the description of the distribution of blood lipids in diabetic patients has not been based on population-based surveys. The aim of this study was to describe diabetic dyslipidemia in a large unselected sample of patients from the Swedish National Diabetes Register.
Methods: Blood lipid profiles and clinical characteristics in 75,048 type 2 diabetic patients (57% men) were studied.
Results: Pronounced hypertriglyceridemia (triglycerides >4.0mmol/l) was seen in 3.4% of the patients. Total cholesterol (TC), LDL-cholesterol (LDL-C), HDL-cholesterol (HDL-C) and non-HDL-C were generally higher, and LDL-C/HDL-C and Non-HDL-C/HDL-C ratios were lower in women. Mean TC, LDL-C as well as HDL-C values were lower in patients treated with lipid-lowering agents, whereas triglycerides was higher than in the untreated patients. In patients not treated with lipid-lowering agents all blood lipids increased in women and decreased in men (except HDL-C) at higher ages. Patients with LDL-C/HDL-C ratio ≥ 3 were slightly younger, less frequently used lipid-lowering drugs and had not so often a history of coronary heart disease or stroke.
Conclusion: The distribution of blood lipids in this large sample of unselected type 2 diabetic patients challenges the previous conception of diabetic dyslipidemia, and calls for new studies to explain the roles of LDL-C and HDL-C as strong cardiovascular risk factors in type 2 diabetes.
DeckertTPoulsenJELarsenM. Prognosis of diabetics with diabetes onset before the age of thirty-one. I. Survival, causes of death, and complications. Diabetologia1978; 14: 363–370.
2.
MorrishNJStevensLKHeadJFullerJHJarrettRJKeenH. A prospective study of mortality among middle-aged diabetic patients (the London Cohort of the WHO Multinational Study of Vascular Disease in Diabetics) II: associated risk factors. Diabetologia1990; 33: 542–548.
3.
American Diabetes Association. Standards of medical care in diabetes-2008. Diabetes care2008; 31(suppl 1): S12–S54.
4.
GrahamIAtarDBorch-JohnsenKBoysenGBurellGCifkovaR. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil2007; 14(Suppl 2): S1–S113.
5.
KraussRM. Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care2004; 27: 1496–1504.
6.
HaffnerSMLehtoSRonnemaaTPyoralaKLaaksoM. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl Med1998; 339: 229–234.
7.
HowardBVRobbinsDCSieversMLLeeETRhoadesDDevereuxRB. LDL cholesterol as a strong predictor of coronary heart disease in diabetic individuals with insulin resistance and low LDL: The Strong Heart Study. Arterioscler Thrombos, Vasc Biol2000; 20: 830–835.
KannelWB. Lipids, diabetes, and coronary heart disease: insights from the Framingham Study. Am Heart J1985; 110: 1100–1107.
10.
CederholmJEeg-OlofssonKEliassonBZetheliusBNilssonPGudbjörnsdóttirS. Risk prediction of cardiovascular disease in type 2 diabetes: A risk equation from the Swedish National Diabetes Register (NDR). Diabetes Care2008; 31: 2038–2043.
11.
Eeg-OlofssonKCederholmJNilssonPNunezLGudbjörnsdottirSEliassonB. Overweight, obesity and cardiovascular complications and death in type 2 diabetes. An observational study in 10 896 patients from the National Diabetes Register (NDR) in Sweden. Diabetologia2009; 52: 65–73.
12.
NilssonPMCederholmJEeg-OlofssonKEliassonBZetheliusBFagardR. Smoking as an independent risk factor for myocardial infarction or stroke in type 2 diabetes: a report from the Swedish National Diabetes Register (NDR). Eur J Cardiovasc Prev Rehabil2009; 16: 506–512.
13.
FriedewaldWTLevyRIFredricksonDS. Estimation of the concentration of low-density lipoprotein cholesteroi in plasma, without use of the preparative ultracentrifuge. Clin Chem1972; 18: 499–502.
JousilahtiPVartiainenETuomilehtoJPuskaP. Sex, age, cardiovascular risk factors, and coronary heart disease: a prospective follow-up study of 14 786 middle-aged men and women in Finland. Circulation1999; 99: 1165–1172.
16.
JuutilainenAKortelainenSLehtoSRonnemaaTPyoralaKLaaksoM. Gender difference in the impact of type 2 diabetes on coronary heart disease risk. Diabetes Care2004; 27: 2898–2904.
17.
NatarajanSLiaoYCaoGLipsitzSRMcGeeDL. Sex differences in risk for coronary heart disease mortality associated with diabetes and established coronary heart disease. Arch Intern Med2003; 163: 1735–1740.
18.
StamlerJStamlerRNeatonJDWentworthDDaviglusMLGarsideD. Low risk-factor profile and long-term cardiovascular and noncardiovascular mortality and life expectancy: findings for 5 large cohorts of young adult and middle-aged men and women. JAMA1999; 282: 2012–2018.
19.
WalldiusGJungnerIHolmeIAastveitAHKolarWSteinerE. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet2001; 358: 2026–2033.
20.
BennMNordestgaardBGJensenGBTybjaerg-HansenA. Improving prediction of ischemic cardiovascular disease in the general population using Apolipoprotein B. The Copenhagen City Heart Study. Arterioscler, Thromb, Vasc Biol2007; 27: 661–670.
21.
CarrollMDLacherDASorliePDCleemanJIGordonDJWolzM. Trends in serum lipids and lipoproteins of adults, 1960-2002. JAMA2005; 294: 1773–1781.
22.
ZhangLQiaoQTuomilehtoJHammarNAlbertiKGMMEliassonM. Blood lipid levels in relation to glucose status in European men and women without a prior history of diabetes: The DECODE Study. Diabetes Res Clin Pract2008; 82: 364–377.
23.
EliassonMJanlertUJanssonJHStegmayrB. Time trends in population cholesterol levels 1986-2004: influence of lipid-lowering drugs, obesity, smoking and educational level. The northern Sweden MONICA study. J Intern Med2006; 260: 551–559.
24.
KanayaAMGradyDBarrett-ConnorE. Explaining the sex difference in coronary heart disease mortality among patients with type 2 diabetes mellitus: a meta-analysis. Arch Intern Med2002; 162: 1737–1745.
25.
GrahamIAtarDBorch-JohnsenKBoysenGBurellGCifkovaR. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J2007; 28: 2375–2414.
26.
RydenLStandlEBartnikMVan den BergheGBetteridgeJde BoerMJ. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J2007; 28: 88–136.
27.
GudbjornsdottirSEeg-OlofssonKCederholmJZetheliusBEliassonBNilssonPM. Risk factor control in patients with Type 2 diabetes and coronary heart disease: findings from the Swedish National Diabetes Register (NDR). Diabet Med2009; 26: 53–60.
28.
HermansMPVan MieghemWVandenhovenGVissersE. Centralized Pan-European survey on the undertreatment of hypercholesterolaemia (CEPHEUS). Acta Cardiol2009; 64: 177–185.
29.
GaedePLund-AndersenHParvingHHPedersenO. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med2008; 358: 580–591.
KontushAChapmanMJ. Antiatherogenic small, dense HDL-guardian angel of the arterial wall?Nat Clin Pract Cardiovasc Med2006; 3: 144–153.
32.
HoangAMurphyAJCoughlanMTThomasMCForbesJMO'BrienR. Advanced glycation of apolipoprotein A-I impairs its anti-atherogenic properties. Diabetologia2007; 50: 1770–1779.
33.
NavabMAnantharamaiahGMReddySTLentenBJVFogelmanAM. HDL as a biomarker, potential therapeutic target, and therapy. Diabetes2009; 58: 2711–2717.
34.
TaskinenM-R. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia2003; 46: 733–749.
35.
SnidermanADBlankDZakarianRBergeronJFrohlichJ. Triglycerides and small dense LDL: the twin Achilles heels of the Friedewald formula. Clin Biochem2003; 36: 499–504.
